2012
DOI: 10.1016/j.critrevonc.2012.02.006
|View full text |Cite
|
Sign up to set email alerts
|

Tailored strategies for radiation therapy in classical Hodgkin's lymphoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
3
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 91 publications
(107 reference statements)
0
3
0
Order By: Relevance
“…Given the very high rates of early PET‐negativity, a few cycles of ABVD DD‐DI could be optimally and safely implemented by earlier consolidation with brentuximab‐vedotin or other targeted‐agents. Beyond this, availability of an improved ABVD platform allowing omission of consolidation radiotherapy may be advantageous in health‐care settings where the availability of updated radiation delivery modalities is problematic (Terezakis & Kasamon, ). Given that access to novel agents to implement standard ABVD and the highly specialized supportive measures advocated by GHSG investigators to fully exploit survival benefit from escalated BEACOPP may not apply to all health‐care systems worldwide (Skoetz et al , ), ABVD DD‐DI may represent a sound and affordable option for high‐risk patients with HL.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Given the very high rates of early PET‐negativity, a few cycles of ABVD DD‐DI could be optimally and safely implemented by earlier consolidation with brentuximab‐vedotin or other targeted‐agents. Beyond this, availability of an improved ABVD platform allowing omission of consolidation radiotherapy may be advantageous in health‐care settings where the availability of updated radiation delivery modalities is problematic (Terezakis & Kasamon, ). Given that access to novel agents to implement standard ABVD and the highly specialized supportive measures advocated by GHSG investigators to fully exploit survival benefit from escalated BEACOPP may not apply to all health‐care systems worldwide (Skoetz et al , ), ABVD DD‐DI may represent a sound and affordable option for high‐risk patients with HL.…”
Section: Discussionmentioning
confidence: 99%
“…Despite impressive cure rates obtained with modern chemotherapy, the optimal therapeutic strategy in advanced classic Hodgkin Lymphoma (HL) is still debated due to some remaining open issues (Longo, ). These involve the best choice of upfront chemotherapy (Bauer et al , ; Borchmann et al , ; Uhm & Kuruvilla, ), the duration and intensity of frontline treatment (Carde et al , ; Connors, ; Borchmann et al , ), the value of consolidation radiotherapy (Aleman et al , ; Johnson et al , ; Engert et al , ; Terezakis & Kasamon, ), the role of functional imaging in treatment planning and monitoring (Dann et al , ; Avigdor et al , ; Gallamini & Kostakoglu, ) and the adequacy of risk stratification tools (Moccia et al , ; Scott et al , ).…”
mentioning
confidence: 99%
See 1 more Smart Citation